Nestimate | $3,000,000 | (Sep 16, 2025)
MedSetGo | $2,400,000 | (Sep 16, 2025)
MarqVision (YC S21) | $48,000,000 | (Sep 16, 2025)
Hopewell Therapeutics, Inc.
United States
- Woburn, Massachusetts
- 08/06/2023
- Unknown
- $25,000,000
Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. We are developing our own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.
- Industry Biotechnology
- Website https://www.hopewell-tx.com/
- LinkedIn https://www.linkedin.com/company/hopewell-therapeutics-inc/
HALA | $157,000,000 | (Sep 16, 2025)
Pascal AI Labs | $3,100,000 | (Sep 16, 2025)
Mazlo | $4,500,000 | (Sep 16, 2025)
Opticore Inc | $7,500,000 | (Sep 16, 2025)
uiAgent | $4,600,000 | (Sep 16, 2025)
Spara | $15,000,000 | (Sep 16, 2025)
resbiotic | $14,500,000 | (Sep 16, 2025)
Dig Energy, Inc. | $5,000,000 | (Sep 16, 2025)
Marloo | $2,700,000 | (Sep 16, 2025)